ARTICLE | Distillery Therapeutics

Therapeutics: BET bromodomain proteins; bromodomain containing 4 (BRD4); histone deacetylase (HDAC)

October 15, 2015 7:00 AM UTC

Mouse and cell culture studies suggest combining BRD4 inhibition with the HDAC inhibitor Zolinza vorinostat could help treat pancreatic cancer. BRD4 levels were higher in pancreatic tumors from a mouse model of the cancer than in pancreatic tissue from normal mice. In a human pancreatic cancer cell line, a tool compound that inhibits BET bromodomain proteins and Zolinza increased markers of apoptosis and decreased growth and BRD4 levels compared with either agent alone or vehicle. In a mouse xenograft model of pancreatic cancer, the BET inhibitor and Zolinza decreased tumor volume. Next steps include testing the combination of BET inhibition and Zolinza in other cancer models...